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Abstract
Vogt-Koyanagi-Harada (VKH) disease is an autoimmune disorder characterized 
by bilateral intraocular inflammation, exudative retinal detachments, and extra-
ocular manifestations in the auditory, integumentary, and central nervous systems 
(CNS). This condition is driven by T-cell-mediated autoimmunity directed against 
melanocytes present in the uveal tissue, in a specific genetic context. The diagnosis is 
based on clinical presentation, accounting with a set of standardized diagnostic cri-
teria. Studies have reported that patients who have a significant delay in the diagnosis 
and/or clinical signs of the chronic stage of the disorder have a poorer prognosis and 
thus special efforts have to be performed in order to have an early diagnosis, together 
with an appropriate treatment. In that sense, the development of tools that allow us 
to detect this disease and its degree of severity is extremely important. In this line, 
novel candidate biomarkers—such as quantification of mRNA levels of NOD and 
glucocorticoid receptor—have been recently reported, and they represent significant 
advances that can help the clinician to improve patient categorization and outcomes.
Keywords: Vogt-Koyanagi-Harada disease, VKH, vitiligo, treatment response, 
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1. Introduction
Vogt-Koyanagi-Harada (VKH) disease is an inflammatory and autoimmune 
condition characterized by intraocular inflammation, serous retinal detachments, 
and extraocular manifestations at the level of the auditory, integumentary, and 
central nervous systems (CNS) [1–3].
No epidemiological studies have been carried out on this condition. However, it 
has been related to certain geographical areas, such as Latin America and Asia, with 
a significant contribution of native origin. In this regard, its frequency has been 
reported up to 22.4% of uveitis causes in referral centers around the world [4–8].
Recently, significant advances have been reported regarding treatment options 
and novel approaches to evaluate and categorize this group of patients, in order 
to personalize follow-up and management in each subject and thus achieve better 
functional and anatomic outcomes [9].
2. Pathogenesis
The main disease mechanism would be driven by cell-mediated autoimmunity 
directed against melanocyte-related proteins, which are located mainly in the uveal 
tissue, skin, and CNS. A significant body of evidence has been published regarding 
the role of genetic associations. The human leukocyte antigen (HLA) appears as a 
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risk factor for VKH, and particularly HLA-DR alleles have shown more consistent 
data [10, 11]. Moreover, several associations with certain polymorphisms have 
been reported in Chinese population. In this regard, important advances regarding 
the role of genetic background in VKH have been introduced by Yang et al. This 
group has been extensively studying different polymorphisms in VKH in Chinese 
population [12].
Regarding the role of the immune system in VKH pathogenesis, CD4 + lympho-
cytes and key cytokines—such as interleukin-2 and interferon gamma—appear 
to play central roles in the development of autoimmunity against melanocyte-
associated proteins [13–15].
3. Clinical findings
A prodromal stage may precede the ocular involvement. This stage is character-
ized by tinnitus and meningismus, which may include nausea, vomiting, stiffness 
of the neck and back, as well as headache as a frequent symptom. However, despite 
its high frequency, headache cannot be considered as a sufficient criterion for the 
definition of meningismus. By this stage, if lumbar puncture is performed, it may 
be returned with pleocytosis [3, 16].
After this prodromal phase of neurological findings, the disease continues 
toward ocular involvement, presenting bilateral acute panuveitis, with a low grade 
of anterior chamber cells and vitreous haze, and diffuse choroiditis, associated with 
exudative retinal detachments and optic disc swelling [1, 16–18] (Figure 1).
Following this initial uveitic phase, a significant group of patients may develop 
chronic granulomatous inflammation, and progressive depigmentation of the 
fundus resulting in “sunset glow fundus” appearance and/or chorioretinal atrophy 
(Figure 2). These clinical findings frequently result from insufficiently treated 
or from a late diagnosis, and they have been associated with poorer functional 
 outcomes [19–21].
Experimental studies have reported choroidal infiltration of activated lympho-
cytes in patients with “sunset glow fundus,” suggesting a persistent low grade of 
subclinical inflammation, which may be implicated in the mechanism of autoim-
mune-mediated ocular depigmentation and atrophy [22, 23].
In addition, integumentary findings may be seen in some patients. In this regard, 
alopecia, poliosis, and vitiligo are classic signs related to pathological autoimmune 
response directed to pigmented tissues (Figure 3).
Figure 1. 
Color fundus photo showing extensive areas of subretinal fluid and bullous serous retinal detachment in a 
37-year-old female with VKH.
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4. Diagnosis
Diagnosis of VKH involves a comprehensive ophthalmic evaluation, in order to 
confirm the presentation of characteristic findings described above. Importantly, 
the bilateral nature of the condition and the presence of panuveitis, with areas of 
subretinal fluid and/or retinal detachments, as well as the inexistence of evidence 
of alternative diseases are hallmarks of the set of standardized diagnostic criteria 
previously published (Table 1) [3, 9, 24]. In that sense, the presence of integu-
mentary and/or neurological findings defines the category of diagnosis (probable 
Figure 2. 
Extensive fundus depigmentation in a VKH patient after 1 year of disease onset. Note the characteristic “sunset 
glow” appearance of the fundus.
Figure 3. 
Integumentary findings in VKH patients. (A) Areas of vitiligo in the perioral area and (B) poliosis in two 
adult patients with VKH.
1. No previous history of penetrating ocular trauma or surgery
2. No clinical/laboratory evidence suggestive of another ocular condition
3. Ocular findings: bilateral ocular involvement (a or b must be present):
a. Early manifestations:
a.1. Diffuse choroiditis, which may manifest as one of the following: focal areas of subretinal fluid and 
bullous serous retinal detachment
a.2. With equivocal fundus findings, both of the following must be present: characteristic fluorescein retinal 
angiogram findings (focal areas of delay on choroidal perfusion, multifocal areas of pinpoint leakage, large 
placoid areas of hyperfluorescence, pooling within subretinal fluid, optic nerve staining) and diffuse 
choroidal thickening without evidence of posterior scleritis on ultrasonography
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if only ocular findings are found, incomplete if at least an extraocular criteria is 
documented, and complete if all the extraocular criteria may be found) [3, 4, 25].
Despite these previously published diagnostic criteria, a moderate agreement 
among uveitis experts has been recently reported for the diagnosis of VKH, with a 
calculated kappa coefficient of 0.4 [25].
5. Treatment
The cornerstone of the therapy corresponds to the use of systemic corticoste-
roids (CS), based on the following principles: early treatment initiation, intensive 
(initial dose of prednisolone/prednisone of 1 mg/kg/day, with a maximum dose of 
80 mg/day), and prolonged (at least 6 months) [27, 28].
Despite this aggressive therapy with systemic CS, a significant proportion of 
VKH patients present refractoriness, remaining with active inflammation and thus 
requiring immunomodulatory therapy (IMT) [9]. This subset of refractory patients 
has better functional outcomes if an earlier IMT is indicated [9].
Therefore, an early CS-response categorization should be carried out, in order 
to distinguish and to separate subjects with a potential benefit of early IMT initia-
tion. In that sense, some clinical predictive factors of GC refractoriness have been 
described, such as baseline VA ≤ 20/200, fundus depigmentation at diagnosis, and 
chronic disease, which are important facts to be considered in the context of an 
appropriate VKH initial evaluation [9].
Currently, a trend to the use of IMT, as first-line therapy, has been observed, 
with no preference in terms of a specific immunosuppressant [29].
b. Late manifestations:
b.1. History suggestive of prior presence of early manifestations and either both b.2 and b.3 findings or 
multiple signs from b.3
b.2. Ocular depigmentation (either of the following is sufficient): sunset glow fundus or Sugiura sign
b.3. Other ocular signs: nummular chorioretinal scars, retinal pigment epithelium clumping and/or 
migration, or recurrent/chronic anterior uveitis
4. Neurological/auditory findings:
a. Meningismus
b. Tinnitus
c. Pleocytosis on cerebrospinal fluid
5. Integumentary findings (not preceding ocular and neurological involvement):
a. Alopecia
b. Poliosis
c. Vitiligo
Diagnostic categories (criteria 1 and 2 must be always present):
1. Complete: ocular plus neurological/auditory plus integumentary findings
2. Incomplete: ocular plus either neurological/auditory or integumentary findings
3. Probable: only ocular findings
*Modified from Read et al. [3].
Table 1. 
Revised diagnostic criteria for Vogt-Koyanagi-Harada disease*.
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6. Novel biomarkers of treatment response and disease activity
As stated above, systemic CS play a significant role for the management of VKH 
patients. CS have been broadly used for autoimmune and inflammatory diseases. 
It is a family of lipophilic medications that has its main mechanism of action at 
the level of the cellular nucleus, interacting directly with the DNA, enhancing or 
repressing gene expression [30].
Some significant developments have been published regarding potential bio-
markers of treatment response based on the glucocorticoid receptor (GR), which 
is a ligand-dependent transcriptional factor [30]. Urzua et al. have found a distinct 
expression profile of GR isoforms that allows to categorize GC response as early as 
2 weeks [26]. This laboratory-based approach is based on the quantification of mRNA 
levels of GR isoforms in two time points and a ratio calculation between both mea-
surements. Furthermore, an in vitro assay has been developed, using a similar strategy 
based on GR expression measurements after in vitro manipulation of immune cells of 
VKH patients. In that sense, a single blood sample is required, and patient compliance 
is not mandatory since sampling for a second time or a CS systemic therapy is not 
required to perform the experiments (Urzua et al., data not published).
As previously described VKH may present with episodes of subclinical inflam-
mation in which, despite clinical examination may appear with no disease activ-
ity, there is evidence of inflammatory foci at the level of choroid, using ancillary 
testing [17]. Although there have been efforts to standardize clinical examination 
in patients with uveitis, some issues remain, mainly related to the accuracy of 
measurements and subjectivity, especially with the clinical quantification of flare 
and vitreous inflammation [31, 32]. In that sense, a novel laboratory-based tool to 
categorize disease activity in VKH patients has been recently initiated. Following 
previous reports regarding the utility of GR quantification to evaluate treatment 
response in VKH, a protein implicated in this pathway has been studied as a candi-
date biomarker. A phosphatase of the MAPK pathway has been evaluated in differ-
ent in vitro experimental conditions, and it has been found to have an association 
between its expression profile and disease activity in VKH patients (Urzua et al., 
data not published).
Significant evidence has been published regarding potential biomarkers for 
disease activity. In that sense, Yang et al. have reported a higher expression of 
NOD1/NOD2 and osteopontin (a matricellular protein) in patients with active VKH 
in comparison with healthy controls and inactive VKH [33, 34].
These promising biomarkers may help clinicians to make decisions in an inflam-
matory condition, which can present with significant choroidal inflammation with 
the absence of clinical evidence of active inflammation, with a resulting worsening 
in prognosis, in terms of sunset glow fundus and visual outcomes [21].
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